Biofrontera Inc.
NCM: BFRILive Quote
About Biofrontera Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
📊 Fundamental Analysis
Biofrontera Inc. demonstrates a profit margin of -25.3%, which is below the sector average, suggesting competitive pressure.
The company recently reported 36.2% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -141.3%, which indicates that capital utilization is currently under pressure.
At a current price of $1.03, BFRI currently sits at the 76th percentile of its 52-week range (Range: $0.54 - $1.19).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$11.27M
Trailing P/E
--
Forward P/E
-4.48
Beta (5Y)
0.64
52W High
$1.19
52W Low
$0.54
Avg Volume
377K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App